Abstract. Organizing pneumonia (OP) is a type of diffuse interstitial lung disease, which may be induced in the context of several clinical conditions, such as drug reactions, infections, autoimmune diseases and cancer. Coronavirus disease 2019 (COVID-19)-associated OP has been reported as a late-stage consequence of the infection or a histological form of COVID-19-associated pneumonia. Autopsies and postmortem lung biopsies have demonstrated that the majority of patients with COVID-19-associated pneumonia develop secondary OP, and COVID-19-associated pneumonia and OP have common radiological features. The diagnosis of COVID-19-associated OP should be suspected in patients with severe acute respiratory syndrome coronavirus 2 infection who exhibit clinical deterioration following the initial phase of infection and with radiological characteristics of OP who received corticosteroids and had a favorable outcome. The early diagnosis of COVID-19-associated OP may lead to targeted treatment, decreased requirements for ventilatory support and an improved survival rate.

Introduction

Since December, 2019, the new coronavirus disease 2019 (COVID-19) has become a worldwide hazard. The multi-organ manifestations of COVID-19 have been well-established. The most common manifestation is COVID-19-associated pneumonia. Although the majority of cases of COVID-19 are mild, in more severe cases, acute lung damage may be followed by interstitial lung disease, pulmonary fibrosis and chronic lung function impairment (1,2).

Organizing pneumonia (OP) is a type of diffuse interstitial lung disease, which is histopathologically characterized by inflammatory debris in the distal airway containing myofibroblasts, fibroblasts and inflammatory cells embedded in a matrix of connective tissue, and interstitial inflammation of the surrounding lung parenchyma (3). OP may develop in the context of various clinical conditions, such as reactions to medication, infections, connective tissue disorders and solid organ or hematologic malignancies (4). The term cryptogenic OP is used for the primary disease, in which no cause is identified (5). Typical radiological features of OP are peribronchovascular and peripheral ground glass opacities (GGOs) or...
consolidations. These lesions may be migratory and accompanied by nodules, masses and interstitial opacities. Another radiological finding consistent with OP is the reversed halo sign, a central GGO surrounded by a consolidation halo. According to previous research, OP is considered to be in the spectrum of manifestations of acute lung injury (6).

Research on viral-induced OP during severe acute respiratory syndrome coronavirus (SARS), Middle East respiratory syndrome (MERS) and H1N1 infection is extensive (7,8). An increasing number of studies have revealed a link between SARS-coronavirus 2 (CoV-2) infection and OP. COVID-19-associated OP had been previously considered to be a result of COVID-19 infection or a histological type of COVID-19-associated pneumonia (9). Of note, the most common findings on chest computed tomography (CT) scans in patients with COVID-19 are peripheral GGOs, consolidation or both, mostly in bilateral and multifocal distributions that highly resemble a CT pattern of OP (10). Moreover, post-mortem lung pathological examinations have demonstrated that the majority of patients with COVID-19-associated pneumonia have secondary OP (11).

Research concerning COVID-19-associated OP is still limited. The present study reports two cases of patients with COVID-19 with radiological evidence of OP following the initial infection, who responded well to treatment with corticosteroids.

Case report

Case 1. A 51-year-old male patient with no notable previous medical history was admitted to the Emergency Department (ED) of Laiko General Hospital complaining of fever, cough and dyspnea over the last 7 days. The patient had been diagnosed with COVID-19 by reverse transcription polymerase chain reaction (RT-PCR) of a nasopharyngeal swab sample for SARS-CoV-2 4 days prior to his admission. The patient was unvaccinated against SARS-CoV-2.

Upon admission, his body temperature was 37.4˚C, his blood pressure was 120/70 mmHg, his heart rate was 94 beats per minute, his respiratory rate was 32 breaths per minute, and his oxygen saturation (SpO2) was 92% in room air. A chest examination revealed crackles on auscultation in all lung fields. Arterial blood gases analysis revealed a partial pressure of oxygen (pO2) of 56 mmHg, partial pressure of carbon dioxide (pCO2) 31 mmHg, pH 7.51, HCO3 24.7 mmol/l on room air. A chest X-ray revealed diffuse infiltrates in all lung fields (Fig. 1). The laboratory findings included an increased white blood cell (WBC) count (11.22 k/µl; reference range, 4.5-11 k/µl) with neutrophilia (87.4%; reference range, 40-74%) and lymphopenia (6.63%; reference range, 19-48%), elevated C-reactive protein (CRP) levels (151.77 mg/l; reference range, 0-5 mg/l), elevated lactate dehydrogenase (LDH) levels (331 U/l; reference range, 135-225 U/l) and elevated ferritin levels (1,200 ng/ml; reference range, 30-400 ng/ml).

Based on these findings, treatment with intravenous remdesivir (200 mg on the first day, followed by 100 mg daily for the following 4 days) and dexamethasone (6 mg/day) for 10 days was commenced for SARS-CoV-2 infection. The patient also received oxygen therapy with a Venturi mask, delivering an oxygen concentration of 60%. The patient exhibited further respiratory deterioration and required oxygen therapy with a high-flow nasal cannula [oxygen flow rate, 60 l/min; fraction of inspired oxygen (FiO2), 90%]. He also received a single dose of intravenous tocilizumab (400 mg).

The patient’s fever, cough, dyspnea and inflammatory indices improved after the treatment was commenced, and on day 8 of hospitalization (day 15 of illness), his SpO2 was 97% while breathing through a high-flow nasal cannula with lower settings (oxygen flow rate, 40 l/min; FiO2, 70%). However, on day 14 of hospitalization (day 21 of illness), he developed rapidly progressive respiratory failure, and his SpO2 decreased to 90%; He thus required oxygen therapy with a high-flow nasal cannula at maximum settings (oxygen flow rate, 60 l/min; FiO2, 100%).

The patient underwent a new chest X-ray which revealed worsening infiltrates in all lung fields (Fig. 2A). He also underwent a chest CT scan and chest computed pulmonary angiogram (CTPA), which revealed bilateral peripheral GGO infiltrates and consolidation in both lower lung lobes, with areas of reversed halo sign (Fig. 2B-D). There were no findings suggesting pulmonary embolism. Simultaneously with this radiological and respiratory deterioration, the patient presented with recurrent fever and significantly elevated CRP levels (279.31 mg/l; reference range, 0-5 mg/l). He received antimicrobial therapy with intravenous piperacillin-tazobactam at 4.5 g four times daily and intravenous linezolid 600 mg twice daily. Blood and sputum culture did not reveal any infectious microorganisms. In addition, serum procalcitonin levels were within the normal range. The patient did not exhibit any improvement with antibiotics. Based on clinical and radiological data, COVID-19-associated OP was suspected, and systemic corticosteroid therapy (methylprednisolone 1 mg/kg/day) was initiated. On day 23 of hospitalization (day 30 of illness), 3 days following the commencement of corticosteroid therapy, his oxygenation level markedly improved. A chest X-ray and CT imaging performed on day 14 following the commencement of corticosteroid therapy (day 34 of illness) revealed an improvement of lung infiltrates (Fig. 3). The levels of CRP also returned to normal. The methylprednisolone administration was decreased to 40 mg, and the patient was discharged on day 39 following admission (day 46 of illness). Following discharge, the methylprednisolone administration was decreased to 32 mg for 10 days, 16 mg for 10 days and...
Figure 3. Chest X-ray and computed tomography of the patient in case 1 performed on day 14 following the commencement of corticosteroid therapy. (A) Chest X-ray illustrating an improvement in lung infiltrates in all lung fields. (B) Chest computed tomography reveals improvement in bilateral peripheral ground glass infiltrates in upper lung lobes. (C and D) Chest computed tomography illustrating consolidation in both lower lung lobes, with areas of reverse halo sign.

Figure 2. Chest X-ray and computed tomography of the patient in case 1 on day 14 of hospitalization. (A) Chest X-ray illustrating lung infiltrates in all lung fields. (B) Chest computed tomography illustrating bilateral peripheral ground glass infiltrates in upper lung lobes. (C and D) Chest computed tomography illustrating consolidation in both lower lung lobes, with areas of reverse halo sign.

Figure 3. Chest X-ray and computed tomography of the patient in case 1 performed on day 14 following the commencement of corticosteroid therapy. (A) Chest X-ray illustrating an improvement in lung infiltrates in all lung fields. (B) Chest computed tomography reveals improvement in bilateral peripheral ground glass infiltrates in upper lung lobes. (C and D) Chest computed tomography reveals improvement in lung lesions compared to Fig. 2C and D.
Based on these findings, treatment with intravenous remdesivir (200 mg on the first day, followed by 100 mg daily for the following 4 days) and dexamethasone (6 mg/day) was commenced for SARS-CoV-2 infection for 10 days. The patient also received oxygen therapy with a Venturi mask, delivering an oxygen concentration of 60%. The patient exhibited further respiratory deterioration with a further elevation of CRP levels (174 mg/l; reference range, 0-5 mg/l) on the second day of hospitalization (day 15 of illness) and required oxygen therapy with a high-flow nasal cannula (oxygen flow rate, 60 l/min; FiO2, 90%). He also received antimicrobial treatment with intravenous ceftriaxone at 2 g once daily and linezolid 600 mg twice daily for 7 days.

The patient's clinical symptoms and inflammatory indices (CRP, 17 mg/l; reference range, 0-5 mg/l) improved after commencing the treatment, and on day 10 of hospitalization (day 23 of illness), his SpO2 was 97%, while breathing through a Venturi mask delivering an oxygen concentration of 60%. The patient did not exhibit any further improvement for the following 2 days. On day 13 of hospitalization (day 26 of illness) the patient developed recurrent low-grade fever and a concurrent new increase in CRP levels (49 mg/l; reference range, 0-5 mg/l). The patient underwent a new chest X-ray, which revealed persistent infiltrates in all lung fields with consolidations in the right upper and middle lung field, and in the left middle lung field (Fig. 5A). He also underwent a chest CT scan and CTPA, which revealed bilateral consolidations with areas of reversed halo sign in all lung fields and peripheral GGO infiltrates in both lower lung lobes (Fig. 5B-D). There were no findings suggesting pulmonary embolism. No infectious microorganisms were isolated from blood and sputum cultures. Based on the clinical and radiological data, COVID-19-associated OP was suspected, and systemic corticosteroid therapy (methylprednisolone at 1 mg/kg/day) was initiated on day 15 (day 28 of illness). On day 18, at 3 days following the commencement of corticosteroid therapy (day 31 of illness), his oxygenation level improved considerably. A chest X-ray and CT imaging performed on day 13 following the commencement of corticosteroid therapy (day 28 of hospitalization, day 41 of illness) revealed a notable improvement in previously noted lung infiltrates (Fig. 6). The levels of CRP also returned to normal. Methylprednisolone administration was decreased to 40 mg, and the patient was discharged on day 33 after admission (day 46 of illness). Following discharge, methylprednisolone administration was decreased to 32 mg for 7 days, 16 mg for 7 days and 8 mg for 7 days, and discontinued thereafter. The patient did not present with a relapse and he had improvement in chest X-ray at a follow-up 2 months after discharge (Fig. 7).

Discussion

The present study describes the cases of two individuals who had rapidly worsening respiratory symptoms after the initial phase of COVID-19 infection. In numerous aspects, the patients' symptoms are compatible with those of OP caused by SARS-CoV-2. Following early treatment for their COVID-19 infection, both patients had rapidly deteriorating respiratory symptoms that were not responding to optimal therapy.
Figure 5. Chest X-ray and computed tomography of the patient in case 2 on day 13 of hospitalization. (A) Chest X-ray illustrating persistent infiltrates in all lung fields with consolidations in the right upper and middle lung field and in the left middle lung field. (B and C) Chest computed tomography illustrating bilateral consolidations with areas of reverse halo sign in upper lung fields. (D) Chest computed tomography illustrating bilateral consolidations with areas of reverse halo sign and peripheral ground glass infiltrates in both lower lung lobes.

Figure 6. Chest X-ray and computed tomography of the patient in case 2 performed on day 13 following the commencement of corticosteroid therapy. (A) Chest X-ray illustrating an improvement in lung infiltrates compared to Fig. 5A. (B and C) Chest computed tomography illustrating an improvement in lung infiltrates in upper lung fields. (D) Chest computed tomography reveals improvement in lung infiltrates in both lower lung lobes.
Of note, the patient in case 1 who was younger than the patient in case 2 developed rapidly progressive respiratory failure on the day 14, while the patient in case 2 recovered more easily under the same treatment regimen. Genetic factors may be a possible explanation for this event. Some patients have heritable, single-gene mutations that influence their immune systems. Such distinctive mutations have been detected in numerous cases of young individuals who are healthy, yet suddenly develop a life-threatening infection (12).

Furthermore, no substantial superimposed infection was proven in the patients described herein. Moreover, their condition markedly improved following the initiation of high-dose corticosteroid treatment, suggesting that OP was the cause of their decompensated respiratory symptoms.

Clinical and investigation data regarding COVID-19-associated OP are limited. The diagnosis of OP was made in some cases, by using only radiological data (13-19), and in other cases, by performing transbronchial biopsy and a histological examination of the obtained tissue (14,20-25). The cases of COVID-19-associated organizing pneumonia reported in the literature are summarized in Table I.

A pathological investigation is essential for definitive diagnosis of COVID-19-associated OP, as radiological manifestations of bacterial co-infection and OP may be similar. Therefore, it does not appear plausible to confirm the presence of OP in patients with SARS-CoV-2-related pneumonia based solely on radiological abnormalities (25). However, in both cases present herein, the conduction of lung biopsy was considered extremely dangerous and was thus not performed, due to high hypoxic conditions.

Notably, not every case of OP is confirmed by pathological data, as is well-recognized. The primary goal of a biopsy in individuals with suspected OP is to rule out other possible causes of comparable symptoms. As the histopathologic characteristics of OP are similar to those of other interstitial lung diseases, relying on transbronchial biopsies may increase the risk of OP misdiagnosis or delay (13). Furthermore, the radiographic characteristics of OP are distinct, and a chest CT scan has a good diagnostic accuracy (79%) for OP (26).

A chest CT scan may be beneficial for ruling out complications, such as pulmonary embolism, secondary pneumonia, or OP in patients with SARS-CoV-2 infection who have clinical deterioration despite optimal treatment and ventilatory support, or who have worsening symptoms following an initial recovery. Both patients in the present study waited an average of 21 days (20-22 days) from symptom initiation to undergo a chest CT scan, and their average duration of stay after commencing treatment with steroids was 10 days (5-15 days). In the case that additional imaging analyses are required for such individuals, this time frame may be an attractive approach.

From the beginning of the pandemic, some researchers have expressed their concerns about potential widespread failure to identify and treat COVID-19-associated OP (9). Radiological evidence of OP has been documented during the later course of SARS-CoV-2 infection. In a previous study, the observed prevalence of COVID-19-associated OP was 12.5% (27). In another observational study, the authors studied persistent lung changes following COVID-19 infection and described ongoing symptoms in 39% of participants. In that study, OP was observed in 4.8% of these patients, with significant radiological and clinical improvement following steroid administration (28). In addition, in a study on respiratory intermediate care unit patients, 58% of patients that underwent a chest CT scan had a radiological pattern consistent with OP and a significantly decreased need for intubation and in-hospital mortality compared to those with a GGO pattern (29).

Of note, both patients described herein were unvaccinated against SARS-CoV-2. A recent study demonstrated that vaccination with at least two doses of COVID-19 vaccine was associated with a significant decrease in reporting the most common post-acute COVID-19 symptoms, such as fatigue, headache, weakness and persistent muscle pain (30). However, whether vaccination against SARS-CoV-2 exerts a protective effect against the development of OP following COVID-19 remains to be determined.

The role of corticosteroids in COVID-19-associated pneumonia has been well-established. Dexamethasone therapy is effective for COVID-19-associated pneumonia (31). Methylprednisolone has been reported to increase the survival of hospitalized patients who experience severe COVID-19 pneumonia (31). A previous meta-analysis revealed a positive effect of corticosteroids on short-term mortality and a decrease in the need for mechanical ventilation in patients with COVID-19 (32).

The cornerstone of OP treatment is corticosteroids. Prednisone at a dosage of 0.75-1.5 mg/kg/day for 4 weeks, tapered over a period of 3-6 months, is the current recommendation (33). In COVID-19-associated OP, case reports and case series, including ours, have documented favorable outcomes with corticosteroid treatment, sometimes with high doses and prolonged therapy, often weeks to months (13-19, 22-25). A single-center prospective observational study discovered that almost a quarter of post-COVID-19 pneumonia patients had recurrent dyspnea with radiological signs of OP, and that restarting corticosteroids resulted in clinical and radiological improvement in these patients (27). Of interest, the spontaneous remission of OP without corticosteroid administration has been described in two cases of histologically diagnosed COVID-19-associated OP (20,21).
A previous study demonstrated that approximately one third of OP cases exhibited a complete resolution of lesions at 1-2 months following disease onset, while those with greater areas of consolidation and more extensive lung involvement were more likely to develop fibrotic-like changes (34). There is currently no evidence to indicate that corticosteroid therapy can prevent relapses of OP or minimize the development of residual pulmonary fibrosis in COVID-19-associated OP (35). There has been no research to date, at least to the best of our knowledge, on the impact of corticosteroids on the resolution of COVID-19-related OP and long-term pulmonary outcomes. Large, multicenter randomized control trials are required to determine the optimal time to start, dosage, duration and benefit of corticosteroid therapy in COVID-19-associated OP. Clinicians should take the possible risks and advantages of corticosteroids into account and utilize CT as an evaluation tool for the distinct phases of CT patterns in patients with COVID-19.

In conclusion, the importance of detecting OP arises from the fact that patients who receive treatment with corticosteroids have a better prognosis and outcome. Increasing awareness of this diagnosis may lead to more effective treatment approaches.

Table I. Cases of COVID-19-associated organizing pneumonia identified in the literature.

| Case no. | Author/(Refs.)          | Age (years)/sex | Diagnosis                  | Management | Outcome              |
|----------|-------------------------|-----------------|---------------------------|------------|----------------------|
| 1        | Alsulami _et al_ (13)   | 71/M            | Radiological              | Corticosteroids | Recovery            |
| 2        | Alsulami _et al_ (13)   | 54/M            | Radiological              | Corticosteroids | Recovery            |
| 3        | Alsulami _et al_ (13)   | 57/M            | Radiological              | Corticosteroids | Recovery            |
| 4        | Alsulami _et al_ (13)   | 49/M            | Radiological              | Corticosteroids | Recovery            |
| 5        | Alsulami _et al_ (13)   | 56/F            | Radiological              | Corticosteroids | Recovery            |
| 6        | Alsulami _et al_ (13)   | 83/F            | Radiological              | Corticosteroids | Recovery            |
| 7        | Ng _et al_ (14)         | 58/F            | Radiological              | Corticosteroids | Recovery            |
| 8        | de Oliveira Filho _et al_ (15) | 52/M         | Radiological              | Corticosteroids | Recovery            |
| 9        | de Oliveira Filho _et al_ (15) | 60/F         | Radiological              | Corticosteroids | Recovery            |
| 10       | de Oliveira Filho _et al_ (15) | 63/F         | Radiological              | Corticosteroids | Recovery            |
| 11       | Horii _et al_ (16)      | 70/F            | Radiological              | Corticosteroids | Recovery            |
| 12       | Okamori _et al_ (17)    | 60/M            | Radiological              | Corticosteroids | Recovery            |
| 13       | Okamori _et al_ (17)    | 61/F            | Radiological              | Corticosteroids | Recovery            |
| 14       | Kim _et al_ (18)        | 71/M            | Radiological              | Corticosteroids | Recovery            |
| 15       | Simões _et al_ (19)     | 71/M            | Radiological              | Corticosteroids | Recovery            |
| 16       | Simões _et al_ (19)     | 83/M            | Radiological              | Corticosteroids | Recovery            |
| 17       | Ng _et al_ (14)         | 81/M            | TBLB, histopathological examination | Corticosteroids | Recovery            |
| 18       | Seo _et al_ (20)        | 50/M            | TBLB, histopathological examination | Spontaneous remission | Recovery            |
| 19       | Funk _et al_ (21)       | 49/M            | TBLB, histopathological examination | Spontaneous remission | Recovery            |
| 20       | Golbets _et al_ (22)    | 36/M            | TBLB, histopathological examination | Corticosteroids | Recovery            |
| 21       | Kanaoka _et al_ (23)    | 56/M            | TBLB, histopathological examination | Corticosteroids | Recovery            |
| 22       | Kanaoka _et al_ (23)    | 84/F            | TBLB, histopathological examination | Corticosteroids | Recovery            |
| 23       | Cortés Colorado _et al_ (24) | 62/M       | TBLB, histopathological examination | Corticosteroids | Recovery            |
| 24       | Vadász _et al_ (25)     | 57/M            | TBLB,histopathological examination | Corticosteroids | Recovery            |
| 25       | Vadász _et al_ (25)     | 70/M            | TBLB,histopathological examination | Corticosteroids | Recovery            |
| 26       | Vadász _et al_ (25)     | 76/M            | TBLB, histopathological examination | Corticosteroids | Recovery            |

F, female; M, male; TBLB, transbronchial lung biopsy.
for COVID-19 disease, further reduction of requirements for ventilatory support, and improved survival. Patients with COVID-19 that exhibit a minimal or no improvement despite optimal therapy should be evaluated further with lung imaging, as they may benefit from early diagnosis and targeted treatment. The optimal time for corticosteroid administration, the dose and the duration of therapy need to be addressed.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

SM, SS and IE conceptualized the study. PP, PK, NM, PS, NT and SC obtained medical images, and prepared the tables and figures. VEG, CSi, CSt and AT advised on patient treatment and wrote and prepared the draft of the manuscript. DAS and VEG analyzed patient data and provided critical revisions. CSi, CSt, AT, NM, PK, PP, SC, PS and NT made substantial contributions to conception and design, and analysis and interpretation of data. VEG and SM confirm the authenticity of all contributions to conception and design, and analysis and interpretation of data. VEG and SM confirm the authenticity of all contributions to conception and design, and analysis and interpretation of data. VEG, CSi, CSt and AT advised on patient treatment and VEG analyzed patient data and provided critical revisions. CSi, CSt, AT, NM, PK, PP, SC, PS and NT made substantial contributions to conception and design, and analysis and interpretation of data. VEG and SM confirm the authenticity of all contributions to conception and design, and analysis and interpretation of data.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Written informed was obtained from the patients for the publication of the data. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

Competing interests

DAS is the Editor-in-Chief of the journal, but had no personal involvement in the reviewing process, or any influence in adjudicating on the final decision, for this article. The other authors declare that they have no competing interests.

References

1. Wang F, Kream RM and Stefano GB: Long-term respiratory and neurological sequelae of COVID-19. Med Sci Monit 26: e928996, 2020.
2. Vasarmidi E, Tsitoura E, Spandidos DA, Tzanakis N and Antoniou KM: Pulmonary fibrosis in the aftermath of the COVID-19 era (Review). Exp Ther Med 20: 2557-2560, 2020.
3. Robertson BJ and Hansell DM: Organizing pneumonia: A kaleidoscope of concepts and morphologies. Eur Radiol 21: 2244-2254, 2011.
4. Oikonomou A and Hansell DM: Organizing pneumonia: The many morphological faces. Eur Radiol 12: 1486-1496, 2002.
5. Cottin V and Corder JF: Cryptogenic organizing pneumonia. Semin Respir Crit Care Med 33: 462-475, 2012.
6. Mandal RV, Mark EJ and Kradin RL: Organizing pneumonia and pulmonary lymphatic architecture in diffuse alveolar damage. Hum Pathol 39: 1234-1238, 2008.
7. Cornejo R, Llanos O, Fernández C, Carlos Díaz J, Cardemil G, Salguero J, Luengo C, Tobar E, Romero C and Gámez LR: Organizing pneumonia in patients with severe respiratory failure due to novel A (H1N1) influenza. BMJ Case Rep 2010: bcr0220102708, 2010.
8. Tse GM, To KF, Chan PK, Lo AW, Ng KC, Wu A, Lee N, Wong HC, Mak SM, Chan KF, et al: Pulmonary pathological features in coronavirus associated severe acute respiratory syndrome (SARS). J Clin Pathol 57: 260-265, 2004.
9. Kory P and Kanne JP: SARS-CoV-2 organizing pneumonia: ‘Has there been a widespread failure to identify and treat this prevalent condition in COVID-19?’ BMJ Open Respir Res 7: e000724, 2020.
10. Kanne JP, Little BP, Chung JH, Ellicker BM and Ketai LH: Essentials for radiologists on COVID-19: An update-radiology scientific expert panel. Radiology 296: E113-E114, 2020.
11. Copin MC, Parmentier E, Duburcq T, Poissy J, Mathieu D and Lilie COVID-19 ICU and Anatopathology Group: Time to consider histologic pattern of lung injury to treat critically ill patients with COVID-19 infection. Intensive Care Med 46: 1124-1126, 2020.
12. Andreakos E, Abel L, Vinv DC, Kaja E, Drolet BA, Zhang Q, O’Farrelly C, Novelli G, Rodriguez-Gallego C, Haerynck F, et al: A global effort to dissect the human genetic basis of SARS-CoV-2 infection. Nat Immunol 23: 159-164, 2022.
13. Alsalami F, Dhaliwal I, Mirkobrada M and Nicholson M: Post-Covid-19 organizing pneumonia: Case series for 6 patients with post-COVID interstitial lung disease. J Lung Pulm Respir Res 8: 108-111, 2021.
14. Ng BH, Ban AY, Nik Abeeed NN and Faisal M: Organising pneumonia manifesting as a late-phase complication of COVID-19. BMJ Case Rep 14: e246119, 2021.
15. de Oliveira Filho CM, Vieceli T, de Fraga Bassotto C, da Rosa Barbato JP, Garcia TS and Scheffel RS: Organizing pneumonia: A late phase complication of COVID-19 responding dramatically to corticosteroids. Braz J Infect Dis 25: 101541, 2021.
16. Horii H, Kamada K, Nakakubo S, Yamashita Y, Nakamura J, Nasuhara Y and Konno S: Rapidly progressive organizing pneumonia associated with COVID-19. Respir Med Case Rep 31: 101295, 2020.
17. Okamori S, Lee H, Kondo Y, Akiyama Y, Kabata H, Kaneko Y, Ishii M, Hasegawa N and Fukunaka K: Coronavirus disease 2019-associated rapidly progressive organizing pneumonia with fibrotic feature: Two case reports. Medicine (Baltimore) 99: e21804, 2020.
18. Kim T, Son E, Jeon D, Lee SJ, Lim S and Cho WH: Effectiveness of steroid treatment for SARS-CoV-2 pneumonia with cryptogenic organizing pneumonia-like reaction: A case report. Disaster Med Public Health Prep 26: 1-4, 2020.
19. Simões JP, Alves Ferreira AK, Almeida PM, Trigueiros F, Braz A, Inácio JR, Medeiros FC, Braz S and Pais de Lacerda A: Organizing pneumonia and COVID-19: A report of two cases. J Infect Chemother 54: 208-212, 2022.
20. Seo H, Jung J, Kim MJ, Jang SJ and Kim SH: Radiologically suspected organizing pneumonia in a patient recovering from COVID-19: A case report. Infect Chemother 54: 208-212, 2022.
21. Funk GC, Nell C, Pokieser W, Thaler B, Rainer G and Valipour A: Secondary organizing pneumonia after coronavirus disease 2019: Two cases. Respir Med Case Rep 32: 101359, 2021.
22. Golbets E, Kaplan A, Shafat T, Yagle Y, Jotkowitz Y, Hecker M, Morty RE, Gattenlöhner S, Walmrath HD, Grimminger F, et al: Severe organising pneumonia following COVID-19. Thorax 76: 201-204, 2021.
26. Johkoh T, Müller NL, Cartier Y, Kavanagh PV, Hartman TE, Akira M, Ichikado K, Ando M and Nakamura H: Idiopathic interstitial pneumonias: diagnostic accuracy of thin-section CT in 129 patients. Radiology 211: 555-560, 1999.

27. Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, Fan Y and Zheng C: Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: A descriptive study. Lancet Infect Dis 20: 425-434, 2020.

28. Myall KJ, Mukherjee B, Castanheira AM, Lam JL, Benedetti G, Mak SM, Preston R, Thillai M, Dewar A, Molyneaux PL and West AG: Persistent post-COVID-19 interstitial lung disease. An observational study of corticosteroid treatment. Ann Am Thorac Soc 18: 799-806, 2021.

29. Rocha AS, Meireles M, Vilaça H, Guimarães TC, Martins MD, Santos LR, Castro A and Mesquita M: Outcomes of Covid-19 organizing pneumonia in critically ill patients. J Infect 83: 496-522, 2021.

30. Kuodi P, Gorelik Y, Zayyad H, Wertheim O, Beiruti Wiegler K, Abu Jabal K, Dror AA, Nazzal S, Glikman D and Edelstein M: Association between vaccination status and reported incidence of post-acute COVID-19 symptoms in Israel: A cross-sectional study of patients tested between March 2020 and November 2021. medRxiv: Jan 17, 2022 (Epub ahead of print).

31. RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Stimpson P, Brightling C, Ustianowski A, et al: Dexamethasone in hospitalised patients with Covid-19. N Engl J Med 384: 693-704, 2021.

32. Edalatifard M, Akhtari M, Salehi M, Naderi Z, Jamshidi A, Mostafaei S, Najafizadeh SR, Farhadi E, Jalili N, Esfahani M, et al: Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: Results from a randomised controlled clinical trial. Eur Respir J 56: 2002808, 2020.

33. van Paassen J, Vos IS, Hoekstra EM, Neumann KMI, Boot PC and Arbous SM: Corticosteroid use in COVID-19 patients: A systematic review and meta-analysis on clinical outcomes. Crit Care 24: 696, 2020.

34. Cordier JF: Cryptogenic organising pneumonia. Eur Respir J 28: 422-446, 2006.

35. Wang Y, Jin C, Wu CC, Zhao H, Liang T, Liu Z, Jian Z, Li R, Wang Z, Li F, et al: Organizing pneumonia of COVID-19: Time-dependent evolution and outcome in CT findings. PLoS One 15: e0240347, 2020.